A Phase II Trial of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Pazopanib (Primary)
Indications Alveolar soft part sarcoma; Haemangiosarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
Focus Therapeutic Use

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
19 Apr 2023 Status changed to completed, as per results presented at the 114th Annual Meeting of the American Association for Cancer Research.
19 Apr 2023 Results (n=46; Between September 2019 and October 2020) assessing the molecular characterisation with whole exome and transcriptomic sequencing to identify the determinants of response to durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas, presented at the 114th Annual Meeting of the American Association for Cancer Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com